A new CRISPR therapy has reduced the need for transfusions in beta-thalassaemia.

DNA editing produced a lasting effect in every participant in a clinical trial

A refined gene editing approach has enabled the fetal haemoglobin gene to be switched back on, forming the basis of a new treatment for β-thalassaemia (an inherited genetic blood disorder). Research led by major institutes in China outlines an upgraded gene editing system designed to deliver more accurate alterations while keeping mistakes to a minimum.

CRISPR/Cas9, originally evolved as a bacterial immune defence, is widely used for targeted DNA editing. Yet its use can carry hazards, including unintended breaks elsewhere in the genome. The new method tackles these concerns by replacing Cas9 with a protein that changes individual DNA bases, and by adding safeguards that stop the cell’s own repair machinery from reversing those edits.

β-thalassaemia therapy: activating the fetal haemoglobin gene via gene editing

The study focused on reactivating the fetal haemoglobin gene, which is typically switched off in adulthood. Scientists disrupted a DNA site where an inhibitory protein normally binds, allowing the fetal gene to remain active. Editing was performed on patients’ blood stem cells from people with β-thalassaemia; cells with the desired changes were then transplanted back into the same patients.

The clinical trial enrolled 5 patients. After their edited stem cells were returned, the patients’ existing cells were eliminated using chemotherapy. Within a few weeks, haemoglobin levels began to rise, and every patient met the key success measure: more than 6 months without needing a blood transfusion.

Although the procedure is very expensive, these findings indicate that gene editing is moving from an experimental technique towards the development of multiple therapies. The long-term impact on patients’ quality of life still needs to be assessed, but it is likely to be substantial.